<DOC>
	<DOC>NCT01356589</DOC>
	<brief_summary>This retrospective observational study will assess the incidence of hemoglobin cycling in chronic kidney disease (stage 3, 4, and 5) patients with renal anemia treated with Mircera (methoxy polyethylene glycol-epoetin beta). Data will be collected from each patient from a 9-month treatment period.</brief_summary>
	<brief_title>A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Chronic kidney disease in predialysis (stage 3 and 4) and dialysis Renal anemia treated with Mircera according to label for at least 9 months before date of signed informed consent Participation in an interventional clinical trial within the retrospective observation period Contraindications to Mircera administration as per label or judged by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>